An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
← catalyst calendarNCT04130997 · readout in 2,112 d
Sponsored by TG Therapeutics, Inc. (industry) · TGTX — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
1,100estimated
Sites
86
Countries
Belarus, Croatia, Georgia +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-11-18 | actual | When the study began enrolling |
| Primary completion | 2032-05-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-05-31 | estimated | The whole study's end, after follow-up |
| First posted | 2019-10-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsing Multiple Sclerosis (RMS)
Intervention
- Biological: Ublituximab — also filed as TG-1101
Primary outcome
what the primary-completion date above is the date OFAnnualized Relapse Rate (ARR)
measured Up to Week 336
Publications
- PMID 41697690 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · TGTX's whole pipeline · Catalyst calendar · Every registered study · What changed